Silva MF, Carrilho FJ, Paranaguá-Vezozzo DC, Campos LT, LS Nacif, Diniz MA, Farias AQ, Alves VAF, D’Alburquerque LAC, Ono SK

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 796-802
Archivo PDF: 101.86 Kb.

RESUMEN

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Parkin DM. The global health burden of infection-associated cancer in the year 2002. Int J Cancer 2006; 118: 3030-44.

2. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010; 78: 7-10.

3. Kikuchi L, Chagas AL, Alencar RSSM, Paranaguá-Vezozzo DC, Carrilho FJ. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Antiviral Therapy 2013; 18: 445-9.

4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med 1996; 334: 693-700.

5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-35.

6. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43. Silva MF, et al. , 2014; 13 (6): 796-802 802

7. Llovet JM, Fuster J, Bruix J. Intention-to-Treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.

8. Marrero J, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparisons of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16.

9. Lencioni R. Loco-regional treatment for hepatocellular carcinoma. Hepatology 2010; 52: 762-73.

10. Cho YC, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-9.

11. Lencioni R, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation with percutaneous ethanol injection. Radiology 2003; 228: 235-40.

12. Lin SM, Lin CJ, Lin CC, Hsu YW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol ablation for hepatocellular carcinoma up to 4 cm. Gastroenterology 2004; 127: 1714-23.

13. Shiina S, Teratani T, Obi S, Sato S, Tateischi R, Fujishima T, Ishikawa T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 111-20.

14. Lin SM, Lin CJ, Hsu Cw, Chen YC. Randomized controlled trial comparing percutaneous percutaneous thermal ablation, and percutaneous acetic acid injection to treat hepatocellular carcinoma 3 cm or less. Gut 2005; 54: 1151-6.

15. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010; 52: 380-8.

16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.

17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982; 5: 649-55.

18. Villa E, Moles A, Ferreti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, et al. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32: 233-8.

19. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.

20. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, Salmi A, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Cancer 1992; 15: 925-9.

21. Lencioni R, Bartolozzi Z, Caramella D, Paolicchi A, Carrai M, Maltinti G, Capria A, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Cancer 1995; 76: 1737-46.

22. Khan KN, Yatsuhaschi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269-78.

23. Hou TI, Huang JC, Wu PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003; 7: 770-8.

24. Brunello F, Veltri A, Caruzzi P, Pagano E, Ciccone G, Moretto P, Sacchetto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-35.

25. Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XL, et al. Ethanol ablation of hepatocellular carcinoma up to 5 cm by using a multiprolonged injection needle with high-dose strategy. Radiology 2009; 253: 552-61.

26. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: 67-72.

27. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-60.

28. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.

29. Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RSM, Diniz MA, Alves VAF, et al. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World J Gastroenterol 2014; 20: 1585-93.